GPCR is trading 4.4% down at $54.16 amid broader weakness in risk assets and cautious sentiment across the biotechnology sector.
- H.C. Wainwright recently lowered its price target on Structure Therapeutics, which continues to weigh on the stock despite a lack of fresh company-specific news.
- The broader U.S. market is currently under pressure, leading to a selloff in risk-sensitive assets and high-growth biotech names.